Abstract
BackgroundCystic fibrosis (CF) lung disease is associated with chronic inflammation leading to progress in lung function. Adiponectin is a predominantly anti-inflammatory adipokine that may have a role in CF lung. This study aims to determine total sputum and total plasma adiponectin levels in clinically stable adults CF patients with CFTR I1234V mutation, compared to plasma adiponectin levels in healthy controls and to investigate their correlations with body mass index (BMI) and spirometry in patients with CF.MethodsA cross-sectional study comprises 17 CF patients and 18 healthy controls. Adiponectin levels were measured by magnetic bead-based multiplex assay.ResultsThe mean age of adult CF patients was 22.9 years±3.8 (18–30) and 76.5% CF patients had pancreatic sufficiency. The mean BMI in healthy controls was slightly higher than CF patients. The mean sputum adiponectin level was significantly lower than plasma adiponectin levels in CF patients and healthy controls (p < 0.001), whereas no significant difference in plasma adiponectin levels between CF patients and healthy controls. The mean sputum adiponectin level was observed to be higher in CF patients with pancreatic insufficiency. Sputum adiponectin level was correlated positively with plasma adiponectin level in CF patients (r = 0.47, p = 0.06). Sputum and plasma adiponectin levels in CF patients were correlated negatively with BMI and percentage predicted forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC).ConclusionsSputum adiponectin may provide a minimally invasive tool in the assessment of inflammatory status in CF patients. A further larger study to address any difference in sputum and plasma adiponectin levels among CF patients with pancreatic sufficiency versus pancreatic insufficiency.
Highlights
Cystic fibrosis (CF) lung disease is associated with chronic inflammation leading to progress in lung function
Adiponectin may account in a number of metabolic processes, including glucose and fatty acid metabolism where its levels reduced with increasing obesity, type 2 diabetes, the and cardiovascular disease compared to healthy controls matched by body mass index (BMI) [15,16,17]
We investigated whether stable adult CF patients with mild cystic fibrosis transmembrane conductance regulator (CFTR) genotype with pancreatic sufficiency modulated sputum and plasma adiponectin levels
Summary
Cystic fibrosis (CF) lung disease is associated with chronic inflammation leading to progress in lung function. Adiponectin is a predominantly anti-inflammatory adipokine that may have a role in CF lung. Cystic fibrosis (CF) is the most common life-shortening genetic disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene leading to altered chloride ion exchange and mucus hypersecretion in the affected organs [1]. CF-associated lung disease is characterized by multiple alterations including hyper viscous mucus, and chronic neutrophilic inflammation with recurrent bacterial infections, mainly caused by Pseudomonas aeruginosa and Staphylococcus aureus and associated with reduced lung function [6,7,8,9,10,11]. Adiponectin may account in a number of metabolic processes, including glucose and fatty acid metabolism where its levels reduced with increasing obesity, type 2 diabetes, the and cardiovascular disease compared to healthy controls matched by BMI [15,16,17]. Its properties are mediated by specific receptors that are widely expressed with AdipoR1, AdipoR2, and T-cadherin being present on epithelial and endothelial pulmonary cells, expressing potentially a vital role in lung physiology [18, 19]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
